Cure of Helicobacter pylori infection in the elderly: effects of eradication on gastritis and serological markers
Background: Specific data on anti‐H. pylori treatments in elderly people are very scarce. The aim of the study was to evaluate in the elderly the efficacy of different anti‐H. pylori therapies and the behaviour of serum anti‐H. pylori antibodies, pepsinogen A and C, and PGA/PGC ratio induced by the...
Gespeichert in:
| Veröffentlicht in: | Alimentary pharmacology & therapeutics 1996-12, Vol.10 (6), p.1021-1027 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1027 |
|---|---|
| container_issue | 6 |
| container_start_page | 1021 |
| container_title | Alimentary pharmacology & therapeutics |
| container_volume | 10 |
| creator | PILOTTO, A. DI MARIO, F. FRANCESCHI, M. LEANDRO, G. SOFFIATI, G. SCAGNELLI, M. BOZZOLA, L. VALERIO, G. |
| description | Background: Specific data on anti‐H. pylori treatments in elderly people are very scarce. The aim of the study was to evaluate in the elderly the efficacy of different anti‐H. pylori therapies and the behaviour of serum anti‐H. pylori antibodies, pepsinogen A and C, and PGA/PGC ratio induced by the anti‐H. pylori treatment.
Methods: One hundred and twenty‐one dyspeptic patients aged >60 years (mean age, 73 years; range, 61–89 years) with H. pylori‐positive gastric ulcers (17 patients), duodenal ulcers (33 patients) or chronic gastritis (71 patients) were treated with one of the following anti‐H. pylori treatments: (A) omeprazole 20 mg/day plus azithromycin 500 mg/day for 3 days; (B) omeprazole 20 mg/day plus azithromycin 500 mg/day for 3 days plus metronidazole 250 mg q.d.s. for 7 days; (C) omeprazole 40 mg/day plus azithromycin 500 mg/day for 3 days plus metronidazole 250 q.d.s. for 7 days; (D) omeprazole 20 mg/day plus clarithromycin 250 b.d. for 7 days; (E) omeprazole 20 mg/day plus clarithromycin 250 b.d. for 7 days plus metronidazole 250 q.d.s. for 7 days; and (F) omeprazole 40 mg/day plus clarithromycin 250 mg b.d. for 7 days plus metronidazole 250 mg q.d.s. for 7 days. At the baseline and 2 months after therapy, endoscopy and serum anti‐H. pylori antibodies, pepsinogen A and C, and PGA/PGC ratio were measured.
Results: Ten patients (8.2%) dropped out of the study. Six patients (4.9%) reported side‐effects. The eradication rates of the six regimens, expressed using intention‐to‐treat and per protocol analysis, were, respectively: (A) 39% and 44%; (B) 50% and 56%; (C) 65% and 77%; (D) 47% and 50%; (E) 85% and 90%; and (F) 83% and 87%. The triple therapy for regimens E and F was significantly more effective than dual therapies (regimens A and D; intention‐to‐treat=P |
| doi_str_mv | 10.1046/j.1365-2036.1996.88260000.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78627614</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78627614</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4668-5c7ce91f1102e55e718e61cebfeb830665e9580a5d56722f75fe6538d942cba93</originalsourceid><addsrcrecordid>eNqVkF1rHCEUhiW0JNukPyEgtPRupn6MjpNAICxtUwi0F8m1OM4xceuOG52l2X9fp7vd-4qg8D6vHh6EPlBSU9LIz6uacikqRrisadfJWikmSVn16wlaHLM3aEGY7CqmKD9D73JeFUS2hJ2iU9W1lBOxQC_LbQIcHb6D4G3sjZ0g4c0uxOSxHx3Yycex3PD0DBjCACnsrjC4OclzEZIZvDV_sbKfTJ6Sn3zGZhxwhhRDfCp5wGuTfkHKF-itMyHD-8N5jh6_fnlY3lX3P759X97eV7aRUlXCthY66iglDISAliqQ1ELvoFecSCmgE4oYMQjZMuZa4UAKroauYbY3HT9Hn_bvblJ82UKe9NpnCyGYEeI261ZJ1kraFPB6D9oUc07g9Cb5MuxOU6Jn4XqlZ6l6lqpn4fqfcP1a2peHb7b9GoZj92C45B8PucnFgktmtD4fMSaYaPiM3eyx3z7A7n8m0Lc_H5TifwCUxZ1k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78627614</pqid></control><display><type>article</type><title>Cure of Helicobacter pylori infection in the elderly: effects of eradication on gastritis and serological markers</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>PILOTTO, A. ; DI MARIO, F. ; FRANCESCHI, M. ; LEANDRO, G. ; SOFFIATI, G. ; SCAGNELLI, M. ; BOZZOLA, L. ; VALERIO, G.</creator><creatorcontrib>PILOTTO, A. ; DI MARIO, F. ; FRANCESCHI, M. ; LEANDRO, G. ; SOFFIATI, G. ; SCAGNELLI, M. ; BOZZOLA, L. ; VALERIO, G.</creatorcontrib><description><![CDATA[Background: Specific data on anti‐H. pylori treatments in elderly people are very scarce. The aim of the study was to evaluate in the elderly the efficacy of different anti‐H. pylori therapies and the behaviour of serum anti‐H. pylori antibodies, pepsinogen A and C, and PGA/PGC ratio induced by the anti‐H. pylori treatment.
Methods: One hundred and twenty‐one dyspeptic patients aged >60 years (mean age, 73 years; range, 61–89 years) with H. pylori‐positive gastric ulcers (17 patients), duodenal ulcers (33 patients) or chronic gastritis (71 patients) were treated with one of the following anti‐H. pylori treatments: (A) omeprazole 20 mg/day plus azithromycin 500 mg/day for 3 days; (B) omeprazole 20 mg/day plus azithromycin 500 mg/day for 3 days plus metronidazole 250 mg q.d.s. for 7 days; (C) omeprazole 40 mg/day plus azithromycin 500 mg/day for 3 days plus metronidazole 250 q.d.s. for 7 days; (D) omeprazole 20 mg/day plus clarithromycin 250 b.d. for 7 days; (E) omeprazole 20 mg/day plus clarithromycin 250 b.d. for 7 days plus metronidazole 250 q.d.s. for 7 days; and (F) omeprazole 40 mg/day plus clarithromycin 250 mg b.d. for 7 days plus metronidazole 250 mg q.d.s. for 7 days. At the baseline and 2 months after therapy, endoscopy and serum anti‐H. pylori antibodies, pepsinogen A and C, and PGA/PGC ratio were measured.
Results: Ten patients (8.2%) dropped out of the study. Six patients (4.9%) reported side‐effects. The eradication rates of the six regimens, expressed using intention‐to‐treat and per protocol analysis, were, respectively: (A) 39% and 44%; (B) 50% and 56%; (C) 65% and 77%; (D) 47% and 50%; (E) 85% and 90%; and (F) 83% and 87%. The triple therapy for regimens E and F was significantly more effective than dual therapies (regimens A and D; intention‐to‐treat=P<0.007, per protocol=P<0.001) or the triple therapy for regimens B and C (intention‐to‐treat=P<0.009, per protocol=P<0.03). Patients cured of H. pylori infection showed a significant decrease in the activity of gastritis (P<0.0001), a significant drop in IgG anti‐H. pylori (P=0.0004) and pepsinogen C (P<0.0001), and an increase in PGA/PGC ratio (P<0.001), while patients remaining H. pylori‐positive showed no changes in the serum parameters.
Conclusions: In the elderly, triple therapy with omeprazole +metronidazole+clarithromycin for 1 week is well tolerated and highly effective; anti‐H. pylori antibody and PGC serum levels decrease soon after anti‐H. pylori therapy only in patients cured of H. pylori infection.]]></description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1046/j.1365-2036.1996.88260000.x</identifier><identifier>PMID: 8971305</identifier><language>eng</language><publisher>Oxford BSL: Blackwell Science</publisher><subject>Aged ; Aged, 80 and over ; Anti-Bacterial Agents - therapeutic use ; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use ; Anti-Ulcer Agents - therapeutic use ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antibodies, Bacterial - blood ; Azithromycin - therapeutic use ; Biological and medical sciences ; Biomarkers - blood ; Clarithromycin - therapeutic use ; Drug Therapy, Combination ; Enzyme Inhibitors - therapeutic use ; Female ; Gastritis - blood ; Gastritis - drug therapy ; Helicobacter Infections ; Helicobacter pylori ; Humans ; Male ; Medical sciences ; Metronidazole - therapeutic use ; Middle Aged ; Omeprazole - therapeutic use ; Pepsinogens - blood ; Pharmacology. Drug treatments</subject><ispartof>Alimentary pharmacology & therapeutics, 1996-12, Vol.10 (6), p.1021-1027</ispartof><rights>Blackwell Science Ltd, Oxford</rights><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4668-5c7ce91f1102e55e718e61cebfeb830665e9580a5d56722f75fe6538d942cba93</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1365-2036.1996.88260000.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1365-2036.1996.88260000.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2525435$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8971305$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>PILOTTO, A.</creatorcontrib><creatorcontrib>DI MARIO, F.</creatorcontrib><creatorcontrib>FRANCESCHI, M.</creatorcontrib><creatorcontrib>LEANDRO, G.</creatorcontrib><creatorcontrib>SOFFIATI, G.</creatorcontrib><creatorcontrib>SCAGNELLI, M.</creatorcontrib><creatorcontrib>BOZZOLA, L.</creatorcontrib><creatorcontrib>VALERIO, G.</creatorcontrib><title>Cure of Helicobacter pylori infection in the elderly: effects of eradication on gastritis and serological markers</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description><![CDATA[Background: Specific data on anti‐H. pylori treatments in elderly people are very scarce. The aim of the study was to evaluate in the elderly the efficacy of different anti‐H. pylori therapies and the behaviour of serum anti‐H. pylori antibodies, pepsinogen A and C, and PGA/PGC ratio induced by the anti‐H. pylori treatment.
Methods: One hundred and twenty‐one dyspeptic patients aged >60 years (mean age, 73 years; range, 61–89 years) with H. pylori‐positive gastric ulcers (17 patients), duodenal ulcers (33 patients) or chronic gastritis (71 patients) were treated with one of the following anti‐H. pylori treatments: (A) omeprazole 20 mg/day plus azithromycin 500 mg/day for 3 days; (B) omeprazole 20 mg/day plus azithromycin 500 mg/day for 3 days plus metronidazole 250 mg q.d.s. for 7 days; (C) omeprazole 40 mg/day plus azithromycin 500 mg/day for 3 days plus metronidazole 250 q.d.s. for 7 days; (D) omeprazole 20 mg/day plus clarithromycin 250 b.d. for 7 days; (E) omeprazole 20 mg/day plus clarithromycin 250 b.d. for 7 days plus metronidazole 250 q.d.s. for 7 days; and (F) omeprazole 40 mg/day plus clarithromycin 250 mg b.d. for 7 days plus metronidazole 250 mg q.d.s. for 7 days. At the baseline and 2 months after therapy, endoscopy and serum anti‐H. pylori antibodies, pepsinogen A and C, and PGA/PGC ratio were measured.
Results: Ten patients (8.2%) dropped out of the study. Six patients (4.9%) reported side‐effects. The eradication rates of the six regimens, expressed using intention‐to‐treat and per protocol analysis, were, respectively: (A) 39% and 44%; (B) 50% and 56%; (C) 65% and 77%; (D) 47% and 50%; (E) 85% and 90%; and (F) 83% and 87%. The triple therapy for regimens E and F was significantly more effective than dual therapies (regimens A and D; intention‐to‐treat=P<0.007, per protocol=P<0.001) or the triple therapy for regimens B and C (intention‐to‐treat=P<0.009, per protocol=P<0.03). Patients cured of H. pylori infection showed a significant decrease in the activity of gastritis (P<0.0001), a significant drop in IgG anti‐H. pylori (P=0.0004) and pepsinogen C (P<0.0001), and an increase in PGA/PGC ratio (P<0.001), while patients remaining H. pylori‐positive showed no changes in the serum parameters.
Conclusions: In the elderly, triple therapy with omeprazole +metronidazole+clarithromycin for 1 week is well tolerated and highly effective; anti‐H. pylori antibody and PGC serum levels decrease soon after anti‐H. pylori therapy only in patients cured of H. pylori infection.]]></description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</subject><subject>Anti-Ulcer Agents - therapeutic use</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antibodies, Bacterial - blood</subject><subject>Azithromycin - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>Clarithromycin - therapeutic use</subject><subject>Drug Therapy, Combination</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>Female</subject><subject>Gastritis - blood</subject><subject>Gastritis - drug therapy</subject><subject>Helicobacter Infections</subject><subject>Helicobacter pylori</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metronidazole - therapeutic use</subject><subject>Middle Aged</subject><subject>Omeprazole - therapeutic use</subject><subject>Pepsinogens - blood</subject><subject>Pharmacology. Drug treatments</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkF1rHCEUhiW0JNukPyEgtPRupn6MjpNAICxtUwi0F8m1OM4xceuOG52l2X9fp7vd-4qg8D6vHh6EPlBSU9LIz6uacikqRrisadfJWikmSVn16wlaHLM3aEGY7CqmKD9D73JeFUS2hJ2iU9W1lBOxQC_LbQIcHb6D4G3sjZ0g4c0uxOSxHx3Yycex3PD0DBjCACnsrjC4OclzEZIZvDV_sbKfTJ6Sn3zGZhxwhhRDfCp5wGuTfkHKF-itMyHD-8N5jh6_fnlY3lX3P759X97eV7aRUlXCthY66iglDISAliqQ1ELvoFecSCmgE4oYMQjZMuZa4UAKroauYbY3HT9Hn_bvblJ82UKe9NpnCyGYEeI261ZJ1kraFPB6D9oUc07g9Cb5MuxOU6Jn4XqlZ6l6lqpn4fqfcP1a2peHb7b9GoZj92C45B8PucnFgktmtD4fMSaYaPiM3eyx3z7A7n8m0Lc_H5TifwCUxZ1k</recordid><startdate>199612</startdate><enddate>199612</enddate><creator>PILOTTO, A.</creator><creator>DI MARIO, F.</creator><creator>FRANCESCHI, M.</creator><creator>LEANDRO, G.</creator><creator>SOFFIATI, G.</creator><creator>SCAGNELLI, M.</creator><creator>BOZZOLA, L.</creator><creator>VALERIO, G.</creator><general>Blackwell Science</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199612</creationdate><title>Cure of Helicobacter pylori infection in the elderly: effects of eradication on gastritis and serological markers</title><author>PILOTTO, A. ; DI MARIO, F. ; FRANCESCHI, M. ; LEANDRO, G. ; SOFFIATI, G. ; SCAGNELLI, M. ; BOZZOLA, L. ; VALERIO, G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4668-5c7ce91f1102e55e718e61cebfeb830665e9580a5d56722f75fe6538d942cba93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</topic><topic>Anti-Ulcer Agents - therapeutic use</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antibodies, Bacterial - blood</topic><topic>Azithromycin - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>Clarithromycin - therapeutic use</topic><topic>Drug Therapy, Combination</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>Female</topic><topic>Gastritis - blood</topic><topic>Gastritis - drug therapy</topic><topic>Helicobacter Infections</topic><topic>Helicobacter pylori</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metronidazole - therapeutic use</topic><topic>Middle Aged</topic><topic>Omeprazole - therapeutic use</topic><topic>Pepsinogens - blood</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>PILOTTO, A.</creatorcontrib><creatorcontrib>DI MARIO, F.</creatorcontrib><creatorcontrib>FRANCESCHI, M.</creatorcontrib><creatorcontrib>LEANDRO, G.</creatorcontrib><creatorcontrib>SOFFIATI, G.</creatorcontrib><creatorcontrib>SCAGNELLI, M.</creatorcontrib><creatorcontrib>BOZZOLA, L.</creatorcontrib><creatorcontrib>VALERIO, G.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>PILOTTO, A.</au><au>DI MARIO, F.</au><au>FRANCESCHI, M.</au><au>LEANDRO, G.</au><au>SOFFIATI, G.</au><au>SCAGNELLI, M.</au><au>BOZZOLA, L.</au><au>VALERIO, G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cure of Helicobacter pylori infection in the elderly: effects of eradication on gastritis and serological markers</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>1996-12</date><risdate>1996</risdate><volume>10</volume><issue>6</issue><spage>1021</spage><epage>1027</epage><pages>1021-1027</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract><![CDATA[Background: Specific data on anti‐H. pylori treatments in elderly people are very scarce. The aim of the study was to evaluate in the elderly the efficacy of different anti‐H. pylori therapies and the behaviour of serum anti‐H. pylori antibodies, pepsinogen A and C, and PGA/PGC ratio induced by the anti‐H. pylori treatment.
Methods: One hundred and twenty‐one dyspeptic patients aged >60 years (mean age, 73 years; range, 61–89 years) with H. pylori‐positive gastric ulcers (17 patients), duodenal ulcers (33 patients) or chronic gastritis (71 patients) were treated with one of the following anti‐H. pylori treatments: (A) omeprazole 20 mg/day plus azithromycin 500 mg/day for 3 days; (B) omeprazole 20 mg/day plus azithromycin 500 mg/day for 3 days plus metronidazole 250 mg q.d.s. for 7 days; (C) omeprazole 40 mg/day plus azithromycin 500 mg/day for 3 days plus metronidazole 250 q.d.s. for 7 days; (D) omeprazole 20 mg/day plus clarithromycin 250 b.d. for 7 days; (E) omeprazole 20 mg/day plus clarithromycin 250 b.d. for 7 days plus metronidazole 250 q.d.s. for 7 days; and (F) omeprazole 40 mg/day plus clarithromycin 250 mg b.d. for 7 days plus metronidazole 250 mg q.d.s. for 7 days. At the baseline and 2 months after therapy, endoscopy and serum anti‐H. pylori antibodies, pepsinogen A and C, and PGA/PGC ratio were measured.
Results: Ten patients (8.2%) dropped out of the study. Six patients (4.9%) reported side‐effects. The eradication rates of the six regimens, expressed using intention‐to‐treat and per protocol analysis, were, respectively: (A) 39% and 44%; (B) 50% and 56%; (C) 65% and 77%; (D) 47% and 50%; (E) 85% and 90%; and (F) 83% and 87%. The triple therapy for regimens E and F was significantly more effective than dual therapies (regimens A and D; intention‐to‐treat=P<0.007, per protocol=P<0.001) or the triple therapy for regimens B and C (intention‐to‐treat=P<0.009, per protocol=P<0.03). Patients cured of H. pylori infection showed a significant decrease in the activity of gastritis (P<0.0001), a significant drop in IgG anti‐H. pylori (P=0.0004) and pepsinogen C (P<0.0001), and an increase in PGA/PGC ratio (P<0.001), while patients remaining H. pylori‐positive showed no changes in the serum parameters.
Conclusions: In the elderly, triple therapy with omeprazole +metronidazole+clarithromycin for 1 week is well tolerated and highly effective; anti‐H. pylori antibody and PGC serum levels decrease soon after anti‐H. pylori therapy only in patients cured of H. pylori infection.]]></abstract><cop>Oxford BSL</cop><pub>Blackwell Science</pub><pmid>8971305</pmid><doi>10.1046/j.1365-2036.1996.88260000.x</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-2813 |
| ispartof | Alimentary pharmacology & therapeutics, 1996-12, Vol.10 (6), p.1021-1027 |
| issn | 0269-2813 1365-2036 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78627614 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Aged Aged, 80 and over Anti-Bacterial Agents - therapeutic use Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Anti-Ulcer Agents - therapeutic use Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Antibodies, Bacterial - blood Azithromycin - therapeutic use Biological and medical sciences Biomarkers - blood Clarithromycin - therapeutic use Drug Therapy, Combination Enzyme Inhibitors - therapeutic use Female Gastritis - blood Gastritis - drug therapy Helicobacter Infections Helicobacter pylori Humans Male Medical sciences Metronidazole - therapeutic use Middle Aged Omeprazole - therapeutic use Pepsinogens - blood Pharmacology. Drug treatments |
| title | Cure of Helicobacter pylori infection in the elderly: effects of eradication on gastritis and serological markers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T12%3A14%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cure%20of%20Helicobacter%20pylori%20infection%20in%20the%20elderly:%20effects%20of%20eradication%20on%20gastritis%20and%20serological%20markers&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=PILOTTO,%20A.&rft.date=1996-12&rft.volume=10&rft.issue=6&rft.spage=1021&rft.epage=1027&rft.pages=1021-1027&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1046/j.1365-2036.1996.88260000.x&rft_dat=%3Cproquest_cross%3E78627614%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78627614&rft_id=info:pmid/8971305&rfr_iscdi=true |